DMPK and myotonic dystrophy type 1: Multiple RNA-based approaches have been investigated to induce the downregulation of the DMPK expanded transcripts (Thornton et al., 2017) and recently CRISPR/CAS9 genome editing technology has been successful applied as a gene therapy approach for DM1 (Provenzano et al., 2017).